Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Worldwide POC Diagnostics Market to Grow

By Labmedica staff writers
Posted on 07 Aug 2006
The worldwide point-of-care (POC) diagnostics market is about to undergo exceptional growth, according to a new report compiled by Cambridge Consultants (Cambridge Science Park, UK).

The report was released following a workshop held in May 2006 by Cambridge Consultants. More...
The participants, who came from across the diagnostics industry, discussed the future of point-of-care testing (POCT) and the role of technology. Attending the 24-hour workshop were delegates from a variety of backgrounds, including clinicians and representatives of diagnostic companies.

Increased availability of accurate, rapid tests, patient demand for instant results, integration with drug delivery technology, and a general shift from lab-based tests to testing in the home, in doctor's surgeries, and over the pharmacy counter were the reasons given for the expected increase in the POCT domestic market.

The delegates questioned whether the technology was adequate. They agreed that the current wet chemistry used in diagnostic testing is adequate and that the barriers to faster adoption lie in post-test data management and quality control. However, the delegation also agreed that new and emerging technologies, such as micro- and nano-technology and novel labels, could revolutionize POCT and diagnostic testing in the future. The group felt that in the meantime those in the industry need to work together to enable doctors and patients to collate the results of the tests. In addition, standardization is necessary to speed adoption of POCT technology, as well as to provide the patient with a common user interface.

The market for POCT differs from region to region. In the United States, defensive medicine dominates, and concerns over liability means that a final confirmatory central test is required. In Europe, adoption depends on clinical benefits and centralized purchasing, and the rate of acceptance is different within each country. In countries like Sweden and Germany, which have decentralized health services, POCT uptake is moving fast with high awareness among doctors and patients. The United Kingdom's difficulty in employing information technology (IT) on time and within budget suggests that countries with similar centralized health services might struggle with POCT adoption.

"Diagnostics could learn a lot from the phone industry,” said Dr. Burnell, diagnostics campaign manager at Cambridge Consultants. "As a group they came together to focus on standardizing aspects of their technology as they realized that this would benefit the customer, as well as the companies who were then free to innovate and add value. The diagnostics industry needs to follow suit and work out a way of providing data from point-of-care devices in a simple and common format.”



Related Links:
Cambridge Consultants

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.